Analyst Mark Massaro of BTIG reiterated a Buy rating on CareDx, with a price target of $26.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mark Massaro has given his Buy rating due to a combination of factors, including CareDx’s solid recent performance and attractive valuation. The company delivered strong fourth-quarter revenue growth driven by higher testing volumes, improved pricing, and record contributions from its patient and digital solutions business, while its shares trade at a significant discount to both historical levels and peers in the diagnostics space.
He also highlights that management’s 2026 revenue outlook exceeds prior expectations even after incorporating a cautious assumption for potential reimbursement headwinds from the CMS LCD, and he believes a favorable final decision could be a further catalyst. In addition, CareDx is investing for long-term growth, including development of its AlloHeme program targeting a meaningful new oncology market, which, combined with raised revenue estimates and a modestly higher price target, underpins Massaro’s positive stance on the stock.